Reviva Pharmaceuticals Holdings (RVPH) Long-Term Debt Issuances (2018)
Reviva Pharmaceuticals Holdings (RVPH) posted Long-Term Debt Issuances of $56045.0 for Q2 2018.
Reviva Pharmaceuticals Holdings (RVPH) Long-Term Debt Issuances (2018) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Long-Term Debt Issuances for 1 years, with the latest figure at $56045.0 in Q2 2018.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $56045.0 in Q2 2018, while the trailing twelve-month figure through Sep 2021 was $56045.0 (changed N/A YoY) and the FY2020 annual result came in at $3.1 million, up 3010.0% from the prior year.
- Long-Term Debt Issuances steadied at $56045.0 in Q2 2018 per RVPH's latest filing.
- Over five years, Long-Term Debt Issuances peaked at $56045.0 in Q2 2018 and troughed at $56045.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2018 | 56,045.00 |
| May 31, 2018 | 56,045.00 |